AOA Dx
S21
Active

AOA Dx

Blood Test for Early Detection of Ovarian Cancer

AOA is developing the first early-stage ovarian cancer blood test so a woman can quickly and accurately be tested to catch the disease earlier when survival rates are 90%. 94% of women with ovarian cancer experience symptoms but current standard of care takes 9 months to diagnose leading to the majority of cases being caught at stage 3 and 4 when survival rates are extremely low. A recently completed 600+ retrospective patient study demonstrated >90% sensitivity and specificity. Each year, 8.5 million women are tested for symptoms of ovarian cancer, creating a $6 billion market. AOA's co-founders have worked together at two previous startups in the women’s health space, both resulting in successful exits upon commercialization. Ovarian cancer is just the beginning. AOA has a platform of novel ganglioside tumor markers to disrupt early cancer detection.

Alex Fisher, COO

Chief Operating Officer & Co-Founder of AOA Dx. Passion about improving women's health.

Alex Fisher
Alex Fisher
AOA Dx

Anna Jeter

Chief Business Officer & Co-Founder

Anna Jeter
Anna Jeter
AOA Dx

Oriana Papin-Zoghbi

CEO & Co-Founder AOA Dx Inc. Passionate about Women's Health.

Oriana Papin-Zoghbi
Oriana Papin-Zoghbi
AOA Dx